(9CI)-5,6,7,8-四氢-8-(1-甲基乙基)-喹啉 | 75414-03-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: (9CI)-5,6,7,8-四氢-8-(1-甲基乙基)-喹啉
• 英文名称: 8-isopropyl-5,6,7,8-tetrahydroquinoline
• 英文别名: 8-propan-2-yl-5,6,7,8-tetrahydroquinoline
• CAS: 75414-03-8
• 化学式: C₁₂H₁₇N
• 分子量: 175.274
• InChiKey: QSIQJZBBKBXYFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  2-异丙基环己酮 在 palladium on activated charcoal lithium aluminium tetrahydride 、 对甲苯磺酸 、 硝基苯 作用下， 以 乙醚 、 乙醇 、 甲苯 、 xylene 为溶剂， 反应 36.0h， 生成 (9CI)-5,6,7,8-四氢-8-(1-甲基乙基)-喹啉
  参考文献：
  名称：

  Hoenel, Michael; Vierhapper, Friedrich W., Journal of the Chemical Society. Perkin transactions I, 1980, p. 1933 - 1939

  摘要：

  DOI：

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• PYRIMIDINONE DERIVATIVE HAVING AUTOTAXIN-INHIBITORY ACTIVITY
  申请人：The University of Tokyo

  公开号：US20170158704A1

  公开（公告）日：2017-06-08

  A compound according to any one of formula (Ia) to (Ic), or its pharmaceutically acceptable salt: wherein R 1 , R 2 , R 3 , R 4a , R 4c , R 5 are as defined in the description.

  根据公式（Ia）至（Ic）中的任一化合物或其药学上可接受的盐： 其中R1、R2、R3、R4a、R4c、R5如描述中所定义。
• NOVEL OLEFIN DERIVATIVE
  申请人：Matsumura Akira

  公开号：US20150246938A1

  公开（公告）日：2015-09-03

  The object of the present invention is to provide novel compounds having ACC2 inhibiting activity. In addition, the object of the present invention is to provide a pharmaceutical composition comprising the compound. A compound of formula (I′): wherein R 1 is substituted or unsubstituted aryl etc., R 2 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 3 is each independently hydrogen, substituted or unsubstituted alkyl etc., n is an integer from 0 to 3, R 12 is hydrogen, substituted or unsubstituted alkyl etc., Ring A is aromatic carbocycle or aromatic heterocycle, R 9 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., m is an integer from 0 to 4, R 4 and R 5 is each independently hydrogen, substituted or unsubstituted alkyl etc., R 6 is substituted or unsubstituted alkyl, substituted or unsubstituted alkenyl etc., R 13 is hydrogen, substituted or unsubstituted alkyl etc., X 5 is bond etc., R 7 is hydrogen or substituted or unsubstituted alkyl, R 8 is substituted or unsubstituted alkylcarbonyl, substituted or unsubstituted alkenylcarbonyl etc.

  本发明的目的是提供具有ACC2抑制活性的新型化合物。此外，本发明的目的是提供包含该化合物的药物组合物。 公式(I′)的化合物： 其中R1是取代或未取代的芳基等， R2各自独立为氢，取代或未取代的烷基等， R3各自独立为氢，取代或未取代的烷基等， n是0到3的整数， R12是氢，取代或未取代的烷基等， 环A是芳香碳环或芳香杂环， R9是取代或未取代的烷基，取代或未取代的烯基等， m是0到4的整数， R4和R5各自独立为氢，取代或未取代的烷基等， R6是取代或未取代的烷基，取代或未取代的烯基等， R13是氢，取代或未取代的烷基等， X5是键等， R7是氢或取代或未取代的烷基， R8是取代或未取代的烷基碳酰，取代或未取代的烯基碳酰等。
• 5-MEMBERED RING HETEROAROMATIC DERIVATIVES HAVING NPY Y5 RECEPTOR ANTAGONISTIC ACTIVITY
  申请人：Hayashi Kyohei

  公开号：US20140051862A1

  公开（公告）日：2014-02-20

  This invention provides new compounds having NPY Y5 antagonistic activity. The present inventors found that a compound of the formula (I): wherein R 1 is substituted or unsubstituted alkyl or the like; p, q and r are each independently 0 or 1; ring A is oxadiazole; and R 2 is substituted or unsubstituted alkyl or the like, has NPY Y5 antagonistic activity.

  这项发明提供了具有NPY Y5拮抗活性的新化合物。现发明人发现，具有以下式（I）的化合物： 其中R1为取代或未取代的烷基或类似物；p、q和r分别独立地为0或1；环A为噁二唑；而R2为取代或未取代的烷基或类似物，具有NPY Y5拮抗活性。
• [EN] ENPP1 MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE L'ENPP1 ET LEURS UTILISATIONS
  申请人：VIR BIOTECHNOLOGY INC

  公开号：WO2021231726A1

  公开（公告）日：2021-11-18

  The disclosure provides compositions and methods of quinoline, quinazolines, and pyrydylpyridines derivatives for the inhibition of ENPP1 modulators.

  该披露提供了有关喹啉、喹唑啉和吡啶吡啶衍生物的组合物和方法，用于抑制ENPP1调节剂。